Clinical pharmacology in neonates: Small size, huge variability
Neonatology: fetal and neonatal research , Volume 105 - Issue 4 p. 344- 349
Drug therapy is a powerful tool for improving neonatal outcome. Despite this, neonatologists still routinely prescribe off-label compounds developed for adults and extrapolate doses from those used for children or adults. Knowledge integration through pharmacokinetic modeling is a method that could improve the current situation. Such predictive models may convert neonatal pharmacotherapy from explorative to confirmatory. This can be illustrated by research projects related to the prediction of neonatal renal clearance and neonatal glucuronidation. This type of model will also improve the current knowledge of neonatal (patho)physiology. In the meanwhile, the fields of clinical pharmacology (e.g. pharmacokinetic/pharmacodynamic modeling and pharmacogenetics) and neonatology (e.g. whole-body cooling and the lower limit of viability) have both matured, resulting in new research topics. However, in order for the modeling and the newly emerging topics to become effective tools, they need to be tailored to the specific characteristics of neonates. Consequently, the field of neonatal pharmacotherapy needs dedicated neonatologists who continue to raise the awareness that off-label practices, eminence-based dosing regimens and the absence of neonatal drug formulations all reflect suboptimal care.
|Neonatal pharmacotherapy, Off-label compounds, Suboptimal care|
|Neonatology: fetal and neonatal research|
|This work was funded by the European Commission 7th Framework Programme; grant id fp7/223614 - Evaluation of antibiotics (ciprofloxacin and fluconazole) for the treatment of infections in preterm and term neonates (TINN), This work was funded by the European Commission 7th Framework Programme; grant id fp7/260908 - Treat Infections in NeoNates 2 - Evaluation of an infective agent (azithromycin) for the treatment of infections in preterm and term neonates (TINN2), This work was funded by the European Commission 7th Framework Programme; grant id fp7/223060 - Efficacy and Safety of Inhaled Budesonide in Very Preterm Infants at Risk for Bronchopulmonary Dysplasia (NEUROSIS)|
|Organisation||Department of Pediatric Surgery|
Allegaert, K.M, & van den Anker, J.N. (2014). Clinical pharmacology in neonates: Small size, huge variability. In Neonatology: fetal and neonatal research (Vol. 105, pp. 344–349). doi:10.1159/000360648